Last updated: August 17, 2026

Examiner: EDGINGTONGIORDANO, FRANCESCA

Tech Center 1600 • Art Units: 1632 1643 1646

This examiner grants 72% of resolved cases

Performance Statistics

71.8%

Allow Rate

+11.8% vs TC avg

138

Total Applications

+30.6%

Interview Lift

1311

Avg Prosecution Days

Based on 103 resolved cases, 2023–2026

4.0%

§101 Eligibility

16.8%

§102 Novelty

29.8%

§103 Obviousness

25.2%

§112 Clarity

App #	Title	Status	Assignee
18274307	Regulation of Butyrophilin subfamily 3 member A1 (BTN3A1, CD277)	Non-Final OA	The Regents of the University of California
17278200	PTPRS AND PROTEOGLYCANS IN RHEUMATOID ARTHRITIS	Non-Final OA	The Regents of the University of California
18580486	PEPTIDES AND ENGINEERED T CELL RECEPTORS TARGETING FANCI, RAD51, AND PBK ANTIGENS AND METHODS OF USE	Non-Final OA	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
17741166	CHIMERIC ANTIGEN RECEPTORS TARGETING CD37	Final Rejection	The General Hospital Corporation

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.